What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?

Oric Pharmaceuticals (ORIC) is identified as a strong momentum stock, holding a Zacks Rank #2 (Buy) and a Momentum Style Score of A. ORIC's stock has significantly outperformed both its industry and the S&P 500, with a 14.08% increase in the past week and a 104.01% increase over the past month, supported by a 20-day average trading volume of 1,988,020 shares; furthermore, earnings estimates have been revised upwards, with the full-year consensus estimate increasing from -$2.06 to -$1.75 in the past 60 days.

Analysis

Oric Pharmaceuticals (ORIC) exhibits strong momentum characteristics, underpinned by a Zacks Rank of #2 (Buy) and a Momentum Style Score of A. The company's stock has demonstrated significant outperformance, with a 14.08% gain in the past week and a notable 104.01% surge over the past month, substantially exceeding the Zacks Medical - Biomedical and Genetics industry's respective increases of 5.43% and 7.54%. This robust price appreciation extends to longer timeframes, with quarterly and annual gains of 28.76% and 25.91% respectively, compared to the S&P 500's 8.33% and 12.92%. Supporting this momentum, ORIC's average 20-day trading volume stands at 1,988,020 shares. Furthermore, the earnings outlook has improved, evidenced by an increase in the full-year consensus estimate from -$2.06 to -$1.75 per share over the past 60 days, driven by five upward earnings estimate revisions against one downward revision. Similar positive revision trends are observed for the next fiscal year, with three upward revisions and one downward, indicating growing analyst confidence.

Key Decisions for Investors

• Given Oric Pharmaceuticals' strong price momentum, #2 (Buy) Zacks Rank, and positive earnings estimate revisions, investors employing momentum strategies may find ORIC an attractive near-term opportunity.
• Investors should monitor the sustainability of the high trading volume, which currently averages 1,988,020 shares over 20 days, and continued positive earnings estimate revisions as key indicators for the persistence of this momentum.
• Despite the bullish signals, including significant outperformance against its industry and the S&P 500, investors should remain cognizant of the inherent volatility associated with biotechnology stocks and the 'buying high, selling higher' nature of momentum investing.